Blood Screening Market

Blood Screening Market by Technology (Nucleic Acid Amplification, (Real Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecast to 2024

Report Code: MD 3687 Dec, 2019, by marketsandmarkets.com

[166 Pages Report] The blood screening market is projected to reach USD 3.3 billion by 2024 from USD 2.2 billion in 2019, at a CAGR of 8.7%. The increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens are the factors majorly driving the growth of this market.

Blood Screening Market, by Region, 2016

Reagents and kits segment to witness the highest growth during the forecast period

Based on product & service, the market is segmented into reagents and kits, instruments, and software and services. The reagents and kits segment has shown the highest growth in the blood screening market and is expected to continue to grow over the forecasted period. This growth is attributed to the accessibility of a wide range of reagents and the need for reliable, specific, and fast detection of TTIs. In addition, the mandate for ELISA testing in several countries, the rising number of blood donations, and the growing demand for blood transfusion for treating blood disorders have contributed to the market growth.

NAT segment accounted for the largest share of the blood screening market, by technology, in 2018

Based on technology, the market is segmented into NAT, ELISA, rapid tests, western blot assays, and NGS. The NAT segment accounted for the larger market share in 2018 and is projected to witness a higher growth rate during the forecast period. This can be attributed to the increasing number of blood donations and the increasing adoption of NAT technology due to its higher sensitivity over other blood screening technologies.

Blood Screening Market, by Region, 2016

North America is the largest regional market for blood screening

On the basis of region, the blood screening market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2018, North America accounted for the largest market share, followed by Europe. Factors such as the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens, the presence of high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the market in North America.

Key Market Players

Prominent players in the blood screening market include Grifols (Spain), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), BioMιrieux (France), Bio-Rad Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US) ,Ortho Clinical Diagnostics, Inc.(US), Becton, Dickinson and Company (US), DiaSorin (Italy), GFE (Germany), Trinity Biotech (Ireland), Merck Millipore (Germany), GE Healthcare (US), Perkin Elmer (US), Bio-Techne Corporation (US), and J Mitra & Co. Pvt. Ltd (India).

Grifols (Spain) is the leading company in the global market for NAT in 2018. The company supplies clinical analysis and laboratory testing tools to laboratories, hospitals, and blood banks worldwide. The company follows organic and inorganic growth strategies such as product launches, mergers, and acquisitions to enhance its market position.

Scope of the Report

Report Metric

Details

Market size available for years

2017–2024

Base year considered

2018

Forecast period

2019–2024

Forecast units

Value (USD)

Segments covered

Product & service, technology, end user, and region

Geographies covered

North America, Europe, Asia Pacific, Latin America and the Middle East and Africa

Companies covered

Grifols (Spain), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), BioMιrieux (France), Bio-Rad Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Ortho Clinical Diagnostics, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), GFE (Germany), Trinity Biotech (Ireland), Merck Millipore (Germany), GE Healthcare (US), Perkin Elmer (US), Bio-Techne Corporation (US), and J Mitra & Co. Pvt. Ltd (India).

This report categorizes the market into the following segments and subsegments:

By Product & Service

  • Reagents and Kits
  • NAT Reagents and Kits
    • Enzymes and Polymerases
    • Standards and Controls
    • Probes and Primers
    • Buffers, Nucleotides, and Solutions
    • Labeling and Detection Reagents
  • ELISA Reagents and Kits
    • Immunosorbents
    • Controls
    • Conjugates
    • Substrates
    • Sample Diluents and Wash Solutions
  • Other Reagents and Kits
  • Instruments
  • Outright Purchase
  • Rental Purchase
  • Software and Services

By Technology

  • NAT
  • Transcription-Mediated Amplification
  • Real-time Polymerase Chain Reaction
  • ELISA
  • Chemiluminescent Immunoassay
  • Fluorescent immunoassay
  • Colorimetric Immunoassay
  • Rapid Tests
  • Western Blot Assays
  • NGS

By End User

  • Blood Banks
  • Hospitals

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • RoLATAM
  • Middle East & Africa

Recent Developments

  • In September 2019, The US FDA approved cobas Babesia, Roche’s first whole-blood test for donor screening, in accordance with May 2019 FDA-updated industry guidance recommending screening and testing for Babesia.
  • In February 2019, Grifols received FDA approval for the Procleix Babesia Assay for donor screening on its Procleix Panther System.
  • In October 2016, Merck opened a new Life Science Center in Burlington, Massachusetts, to serve as a regional hub for scientific advancement and customer collaboration.

Key Questions Addressed by the Report

  • Where will these developments take the industry in the mid-to-long term?
  • What are the recent trends affecting the market?
  • Who are the key players in the market, and how intense is the competition?
  • What are the key applications of blood screening instruments and consumables?
  • Which region is lucrative for the market?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 20)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitation
    1.6 Stakeholders

2 Research Methodology (Page No. - 23)
    2.1 Research Data
    2.2 Research Design
    2.3 Secondary Data
           2.3.1 Secondary Source
    2.4 Primary Data
           2.4.1 Key Data From Primary Sources
    2.5 Market Size Estimation
           2.5.1 Bottom-Up Approach
           2.5.2 Top-Down Approach
           2.5.3 Growth Forecast
    2.6 Market Breakdown and Data Triangulation
    2.7 Assumptions for the Study

3 Executive Summary (Page No. - 30)

4 Premium Insights (Page No. - 33)
    4.1 Blood Screening: Market Overview
    4.2 Asia Pacific: Market Share, By End User & Country (2018)
    4.3 Market, By Product & Service, 2019 Vs. 2024 (USD Million)
    4.4 Geographical Snapshot of the Market

5 Market Overview (Page No. - 36)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing Demand for Donated Blood and Rising Number of Blood Donations
                    5.2.1.2 Rising Prevalence of Infectious Diseases and Introduction of Newer Pathogens
           5.2.2 Opportunities
                    5.2.2.1 Technological Advancements
                    5.2.2.2 Emerging Economies
           5.2.3 Challenges
                    5.2.3.1 Need for Reducing Blood Screening Prices

6 Blood Screening Market, By Product & Service (Page No. - 41)
    6.1 Introduction
    6.2 Reagents & Kits
           6.2.1 NAT Reagents & Kits
                    6.2.1.1 High Sensitivity and Rising use of NAT are Boosting Demand for Related Reagents and Kits
                    6.2.1.2 Enzymes & Polymerases
                    6.2.1.3 Standards & Controls
                    6.2.1.4 Probes & Primers
                    6.2.1.5 Buffers, Nucleotides, & Solutions
                    6.2.1.6 Labeling & Detection Reagents
           6.2.2 Elisa Reagents & Kits
                    6.2.2.1 Ease of use and Cost-Effectiveness of Elisa Reagents & Kits Will Drive Market Growth
                    6.2.2.2 Immunosorbents
                    6.2.2.3 Controls
                    6.2.2.4 Conjugates
                    6.2.2.5 Substrates
                    6.2.2.6 Sample Diluents and Wash Solutions
           6.2.3 Other Reagents
                    6.2.3.1 Increasing use of Western Blot Tests and Rapid Tests Will Drive the Growth of This Market Segment
    6.3 Instruments
           6.3.1 Rental Purchase
                    6.3.1.1 Convenience and Cost-Effectiveness of Renting Instruments has Resulted in Greater End-User Preference
           6.3.2 Outright Purchase
                    6.3.2.1 Availability of Government Support Will Increase the Outright Purchase of Instruments
    6.4 Software & Services
           6.4.1 Increasing Adoption of Instruments Will Drive the Demand for Related Software and Services

7 Blood Screening Market, By Technology (Page No. - 51)
    7.1 Introduction
    7.2 Nucleic Acid Testing (NAT)
           7.2.1 Transcription-Mediated Amplification
                    7.2.1.1 Highest Sensitivity of These Assays to Support Market Growth
           7.2.2 Real-Time Polymerase Chain Reaction (PCR)
                    7.2.2.1 Real-Time PCR Procedures Provide More Accurate and Effective Results as Compared to Conventional PCR
    7.3 Enzyme-Linked Immunosorbent Assays
           7.3.1 Chemiluminescence Immunoassays
                    7.3.1.1 Clia is Ultrasensitive, Automated, and a Good Alternative to Conventional Methodologies
           7.3.2 Fluorescent Immunoassays
                    7.3.2.1 Rising Demand for Safer and Stable Reagents and the Development of Novel Markers to Support the Growth of This Market Segment
           7.3.3 Colorimetric Immunoassays
                    7.3.3.1 CI Offers Low Sensitivity as It Uses Vulnerable/Limited Signal Amplification Strategies
    7.4 Rapid Tests
           7.4.1 Rising Awareness About Rapid Tests in Emerging Countries Have Increased the Adoption of These Tests
    7.5 Western Blot Assays
           7.5.1 Growing Prevalence of TTIS in Developing Countries has Resulted in the Increased Demand for Western Blot Assays
    7.6 Next-Generation Sequencing
           7.6.1 Ngs is an Emerging Technology in the Market

8 Blood Screening Market, By End User (Page No. - 62)
    8.1 Introduction
    8.2 Blood Banks
           8.2.1 Blood Banks Hold the Largest Share of the Market
    8.3 Hospitals
           8.3.1 Increasing Number of Surgical Procedures Will Drive the Growth of the Hospitals Segment

9 Blood Screening Market, By Region (Page No. - 66)
    9.1 Introduction
    9.2 North America
           9.2.1 US
                    9.2.1.1 The US Dominates the Global Market
           9.2.2 Canada
                    9.2.2.1 High Incidence of Sexually Transmitted Diseases in the Country to Support Market Growth
    9.3 Europe
           9.3.1 Germany
                    9.3.1.1 Germany is the Largest Market for Blood Screening Technologies in Europe
           9.3.2 France
                    9.3.2.1 Increasing Prevalence of HIV to Support Market Growth
           9.3.3 UK
                    9.3.3.1 Government Support to Prevent Transmission of HIV and Other Infections Will Drive Growth
           9.3.4 Italy
                    9.3.4.1 Italy is Witnessing an Increase in the Number of Blood Donors
           9.3.5 Spain
                    9.3.5.1 Increasing Adoption of NAT Technology Will Support Market Growth
           9.3.6 RoE
    9.4 Asia Pacific
           9.4.1 China
                    9.4.1.1 China has a High Prevalence of Infectious Diseases
           9.4.2 Japan
                    9.4.2.1 Japan has Witnesses an Increase in the Adoption of Advanced Blood Screening Technologies
           9.4.3 India
                    9.4.3.1 Increasing Number of Road Accidents Will Support Market Growth
           9.4.4 Australia
                    9.4.4.1 Rising Number of Blood Donations Will Propel Market Growth
           9.4.5 Rest of Asia Pacific
    9.5 Latin America
           9.5.1 Brazil
                    9.5.1.1 Increasing Incidence of Cancer Will Support the Growth of This Market
           9.5.2 Rest of Latin America
    9.6 Middle East & Africa
           9.6.1 Rising Prevalence of Infectious Diseases Will Drive Market Growth in the Region

10 Competitive Landscape (Page No. - 114)
     10.1 Overview
     10.2 Market Share Analysis, 2018
             10.2.1 Market Share Analysis for NAT Blood Screening, 2018
             10.2.2 Market Share Analysis for Total Market, 2018
     10.3 Competitive Scenario
             10.3.1 Partnerships, Agreements, and Collaborations (2017–2019)
             10.3.2 Product Launches (2017–2019)
             10.3.3 Expansions (2017–2019)
             10.3.4 Acquisitions (2017–2019)
     10.4 Competitive Leadership Mapping (2019)
             10.4.1 Vendor Inclusion Criteria
             10.4.2 Visionary Leaders
             10.4.3 Innovators
             10.4.4 Dynamic Differentiators
             10.4.5 Emerging Companies

11 Company Profiles (Page No. - 122)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     11.1 Grifols
     11.2 F. Hoffmann-La Roche
     11.3 Abbott Laboratories
     11.4 BioMιrieux
     11.5 Bio-Rad Laboratories
     11.6 Becton, Dickson and Company
     11.7 Danaher Corporation
     11.8 Ortho Clinical Diagnostics
     11.9 Siemens Healthineers
     11.10 Thermo Fisher Scientific
     11.11 DiaSorin
     11.12 GE Healthcare
     11.13 Merck KGaA
     11.14 Perkinelmer
     11.15 Bio-Techne
     11.16 GFE
     11.17 Trinity Biotech
     11.18 J. Mitra Diagnostics Pvt. Ltd.

*Business Overview, Products Offered, Recent Developments, MnM View Might Not be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 159)
     12.1 Discussion Guide
     12.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     12.3 Available Customization
     12.4 Related Reports
     12.5 Author Details


List of Tables (177 Tables)

Table 1 Global Cancer Incidence, 2018 Vs. 2025
Table 2 Blood Screening Market, By Product & Service, 2018–2024 (USD Million)
Table 3 Blood Screening Reagents & Kits Market, By Country, 2018–2024 (USD Million)
Table 4 Blood Screening Reagents & Kits Market, By Type, 2018–2024 (USD Million)
Table 5 NAT Reagents & Kits Market, By Region, 2018–2024 (USD Million)
Table 6 NAT Reagents & Kits Market, By Type, 2018–2024 (USD Million)
Table 7 Elisa Reagents & Kits Market, By Region, 2018–2024 (USD Million)
Table 8 Elisa Reagents & Kits Market, By Type, 2018–2024 (USD Million)
Table 9 Other Reagents & Kits Market, By Region, 2019–2024 (USD Million)
Table 10 Blood Screening Instruments Market, By Region, 2019–2024 (USD Million)
Table 11 Blood Screening Instruments Market, By Mode of Purchase, 2019–2024 (USD Million)
Table 12 Market for Rental Purchase of Blood Screening Instruments, By Country, 2019–2024 (USD Million)
Table 13 Market for Outright Purchase of Blood Screening Instruments, By Country, 2019–2024 (USD Million)
Table 14 Blood Screening Software & Services Market, By Country, 2019–2024 (USD Million)
Table 15 Blood Screening Market, By Technology, 2017–2024 (USD Million)
Table 16 Market for NAT, By Region, 2017–2024 (USD Million)
Table 17 Market for NAT, By Type, 2017–2024 (USD Million)
Table 18 Transcription-Mediated Amplification Market, By Region, 2017–2024 (USD Million)
Table 19 Real-Time PCR Market, By Region, 2017–2024 (USD Million)
Table 20 Market for Elisa, By Region, 2017–2024 (USD Million)
Table 21 Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 22 Chemiluminescence Immunoassays Market, By Region, 2017–2024 (USD Million)
Table 23 Fluorescent Immunoassays Market, By Region, 2017–2024 (USD Million)
Table 24 Colorimetric Immunoassays Market, By Region, 2017–2024 (USD Million)
Table 25 Market for Rapid Tests, By Region, 2017–2024 (USD Million)
Table 26 Blood Screening Market for Western Blot Assays, By Region, 2017–2024 (USD Million)
Table 27 Market for NGS, By Region, 2017–2024 (USD Million)
Table 28 Market, By End User, 2017–2024 (USD Million)
Table 29 Market for Blood Banks, By Region, 2017–2024 (USD Million)
Table 30 Market for Hospitals, By Region, 2017–2024 (USD Million)
Table 31 Market, By Region, 2017–2024 (USD Million)
Table 32 North America: Market, By Country, 2017–2024 (USD Million)
Table 33 North America: Blood Screening Market, By Technology, 2017–2024 (USD Million)
Table 34 North America: Market for NAT, By Type, 2017–2024 (USD Million)
Table 35 North America: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 36 North America: Market, By Product & Service, 2017–2024 (USD Million)
Table 37 North America: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 38 North America: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 39 North America: Market, By End User, 2017–2024 (USD Million)
Table 40 Incidence of Various Cancers in the Us, 2018 Vs.2025
Table 41 US: Market, By Technology, 2017–2024 (USD Million)
Table 42 US: Blood Screening Market for NAT, By Type, 2017–2024 (USD Million)
Table 43 US: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 44 US: Market, By Product & Service, 2017–2024 (USD Million)
Table 45 US: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 46 US: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 47 US: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 48 Canada: Market, By Technology, 2017–2024 (USD Million)
Table 49 Canada: Market for NAT, By Type, 2017–2024 (USD Million)
Table 50 Canada: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 51 Canada: Market, By Product & Service, 2017–2024 (USD Million)
Table 52 Canada: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 53 Canada: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 54 Canada: Market, By End User, 2017–2024 (USD Million)
Table 55 Europe: Market, By Country, 2017–2024 (USD Million)
Table 56 Europe: Market, By Technology, 2017–2024 (USD Million)
Table 57 Europe: Market for NAT, By Type, 2017–2024 (USD Million)
Table 58 Europe: Blood Screening Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 59 Europe: Market, By Product & Service, 2017–2024 (USD Million)
Table 60 Europe: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 61 Europe: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 62 Europe: Market, By End User, 2017–2024 (USD Million)
Table 63 Germany: Market, By Technology, 2017–2024 (USD Million)
Table 64 Germany: Market for NAT, By Type, 2017–2024 (USD Million)
Table 65 Germany: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 66 Germany: Blood Screening Market, By Product & Service, 2017–2024 (USD Million)
Table 67 Germany: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 68 Germany: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 69 Germany: Market, By End User, 2017–2024 (USD Million)
Table 70 France: Market, By Technology, 2017–2024 (USD Million)
Table 71 France: Market for NAT, By Type, 2017–2024 (USD Million)
Table 72 France: Blood Screening Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 73 France: Blood Screening Market, By Product & Service, 2017–2024 (USD Million)
Table 74 France: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 75 France: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 76 France: Market, By End User, 2017–2024 (USD Million)
Table 77 UK: Market, By Technology, 2017–2024 (USD Million)
Table 78 UK: Market for NAT, By Type, 2017–2024 (USD Million)
Table 79 UK: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 80 UK: Blood Screening Market, By Product & Service, 2017–2024 (USD Million)
Table 81 UK: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 82 UK: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 83 UK: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 84 Italy: Market, By Technology, 2017–2024 (USD Million)
Table 85 Italy: Market for NAT, By Type, 2017–2024 (USD Million)
Table 86 Italy: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 87 Italy: Market, By Product & Service, 2017–2024 (USD Million)
Table 88 Italy: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 89 Italy: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 90 Italy: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 91 Spain: Market, By Technology, 2017–2024 (USD Million)
Table 92 Spain: Market for NAT, By Type, 2017–2024 (USD Million)
Table 93 Spain: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 94 Spain: Market, By Product & Service, 2017–2024 (USD Million)
Table 95 Spain: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 96 Spain: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 97 Spain: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 98 RoE: Market, By Technology, 2017–2024 (USD Million)
Table 99 RoE: Market for NAT, By Type, 2017–2024 (USD Million)
Table 100 RoE: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 101 RoE: Blood Screening Market, By Product & Service, 2017–2024 (USD Million)
Table 102 RoE: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 103 RoE: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 104 RoE: Market, By End User, 2017–2024 (USD Million)
Table 105 Asia Pacific: Market, By Country, 2017–2024 (USD Million)
Table 106 Asia Pacific: Market, By Technology, 2017–2024 (USD Million)
Table 107 Asia Pacific: Market for NAT, By Type, 2017–2024 (USD Million)
Table 108 Asia Pacific: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 109 Asia Pacific: Market, By Product & Service, 2017–2024 (USD Million)
Table 110 Asia Pacific: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 111 Asia Pacific: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 112 Asia Pacific: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 113 China: Market, By Technology, 2017–2024 (USD Million)
Table 114 China: Market for NAT, By Type, 2017–2024 (USD Million)
Table 115 China: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 116 China: Market, By Product & Service, 2017–2024 (USD Million)
Table 117 China: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 118 China: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 119 China: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 120 Japan: Market, By Technology, 2017–2024 (USD Million)
Table 121 Japan: Market for NAT, By Type, 2017–2024 (USD Million)
Table 122 Japan: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 123 Japan: Market, By Product & Service, 2017–2024 (USD Million)
Table 124 Japan: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 125 Japan: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 126 Japan: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 127 India: Market, By Technology, 2017–2024 (USD Million)
Table 128 India: Market for NAT, By Type, 2017–2024 (USD Million)
Table 129 India: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 130 India: Market, By Product & Service, 2017–2024 (USD Million)
Table 131 India: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 132 India: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 133 India: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 134 Australia: Market, By Technology, 2017–2024 (USD Million)
Table 135 Australia: Market for NAT, By Type, 2017–2024 (USD Million)
Table 136 Australia: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 137 Australia: Market, By Product & Service, 2017–2024 (USD Million)
Table 138 Australia: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 139 Australia: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 140 Australia: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 141 RoAPAC: Market, By Technology, 2017–2024 (USD Million)
Table 142 RoAPAC: Market for NAT, By Type, 2017–2024 (USD Million)
Table 143 RoAPAC: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 144 RoAPAC: Market, By Product & Service, 2017–2024 (USD Million)
Table 145 RoAPAC: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 146 RoAPAC: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 147 RoAPAC: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 148 Latin America: Market, By Country, 2017–2024 (USD Million)
Table 149 Latin America: Market, By Technology, 2017–2024 (USD Million)
Table 150 Latin America: Market for NAT, By Type, 2017–2024 (USD Million)
Table 151 Latin America: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 152 Latin America: Market, By Product & Service, 2017–2024 (USD Million)
Table 153 Latin America: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 154 Latin America: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 155 Latin America: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 156 Incidence of Various Cancers in Brazil, 2018 Vs.2025
Table 157 Brazil: Market, By Technology, 2017–2024 (USD Million)
Table 158 Brazil: Market for NAT, By Type, 2017–2024 (USD Million)
Table 159 Brazil: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 160 Brazil: Market, By Product & Service, 2017–2024 (USD Million)
Table 161 Brazil: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 162 Brazil: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 163 Brazil: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 164 Rest of Latin America: Market, By Technology, 2017–2024 (USD Million)
Table 165 Rest of Latin America: Market for NAT, By Type, 2017–2024 (USD Million)
Table 166 Rest of Latin America: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 167 Rest of Latin America: Market, By Product & Service, 2017–2024 (USD Million)
Table 168 Rest of Latin America: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 169 Rest of Latin America: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 170 Rest of Latin America: Blood Screening Market, By End User, 2017–2024 (USD Million)
Table 171 MEA: Market, By Technology, 2017–2024 (USD Million)
Table 172 MEA: Market for NAT, By Type, 2017–2024 (USD Million)
Table 173 MEA: Market for Elisa, By Platform, 2017–2024 (USD Million)
Table 174 MEA: Market, By Product & Service, 2017–2024 (USD Million)
Table 175 MEA: Blood Screening Reagents & Kits Market, By Type, 2017–2024 (USD Million)
Table 176 MEA: Blood Screening Instruments Market, By Purchase Type, 2017–2024 (USD Million)
Table 177 MEA: Market, By End User, 2017–2024 (USD Million)
 
 
List of Figures (37 Figures)
 
Figure 1 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 2 Market Size Estimation: Bottom-Up Approach
Figure 3 Market Size Estimation: Top-Down Approach
Figure 4 Data Triangulation Methodology
Figure 5 Blood Screening Market, By Product & Service, 2019 Vs. 2024 (USD Billion)
Figure 6 Market, By Technology, 2019 Vs. 2024 (USD Billion)
Figure 7 Market, By End User, 2019 Vs. 2024 (USD Billion)
Figure 8 Geographic Outlook: Market
Figure 9 Increasing Prevalence of Chronic & Infectious Diseases to Drive Market Growth
Figure 10 Blood Banks Accounted for the Largest Share in the Asia Pacific in 2018
Figure 11 Reagents and Kits Sub Segment Dominates the Blood Screening Products Market
Figure 12 China to Register the Highest CAGR During the Forecast Period
Figure 13 Rise in HIV-Affected Patient Population, 2000–2018
Figure 14 Reagents & Kits Segment is Expected to Hold the Largest Share of the Market During the Forecast Period
Figure 15 NAT Segment Will Continue to Dominate the Blood Screening Market in 2024
Figure 16 Blood Banks Will Continue to Dominate the Market During the Forecast Period
Figure 17 North America: Market Snapshot
Figure 18 Asia Pacific: Market Snapshot
Figure 19 Key Players Adopted Organic as Well as Inorganic Growth Strategies Between 2016 and 2019
Figure 20 Market Evolution Framework
Figure 21 NAT Blood Screening Market Share Analysis, By Key Player, 2018
Figure 22 Market Share Analysis, By Key Player, 2018
Figure 23 Competitive Leadership Mapping
Figure 24 Grifols: Company Snapshot (2018)
Figure 25 F. Hoffman-La Roche: Company Snapshot (2018)
Figure 26 Abbott Laboratories: Company Snapshot (2018)
Figure 27 BioMιrieux: Company Snapshot (2018)
Figure 28 Bio-Rad Laboratories: Company Snapshot (2018)
Figure 29 Becton, Dickson and Company: Company Snapshot (2018)
Figure 30 Danaher Corporation: Company Snapshot (2018)
Figure 31 Siemens Healthineers: Company Snapshot (2018)
Figure 32 Thermo Fisher Scientific: Company Snapshot (2018)
Figure 33 DiaSorin: Company Snapshot (2018)
Figure 34 General Electric: Company Snapshot (2018)
Figure 35 Merck KGaA: Company Snapshot (2018)
Figure 36 Perkinelmer: Company Snapshot (2018)
Figure 37 Bio-Techne Corporation: Company Snapshot (2018)

This study involved four major activities in estimating the current size of the blood screening market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was mainly used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the blood screening market. The secondary sources used for this study include the US Food and Drug Association (US FDA), AVERT, European Commission, Red Cross, Union for International Cancer Control, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), Organisation for Economic Co-operation and Development (OECD), European Centre for Disease Prevention and Control (ECDC), Annual Reports, Press Releases, SEC Filings, Expert Interviews, and Investor Presentations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Blood Screening Market, by Region, 2016

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the blood screening market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the market on the basis of product & service, technology, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to their individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such acquisitions; product launches; expansions; agreements, partnerships, and collaborations; and R&D activities in the market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Market size and growth rate estimates for counties in Rest of Europe and the Rest of Asia Pacific

Company Profiles

  • Additional five company profiles of players operating in the blood screening market
Report Code
MD 3687
Published ON
Dec, 2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Blood Screening Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

...

Digital Virtual Assistant - MarketsandMarkets

Home